Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00372827|
Recruitment Status : Completed
First Posted : September 7, 2006
Last Update Posted : November 21, 2016
|Condition or disease||Intervention/treatment||Phase|
|Primary Open-angle Glaucoma Ocular Hypertension Pigment Dispersion Glaucoma||Drug: Brinzolamide 1% added to Travoprost 0.004%||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||245 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension|
|Study Start Date :||February 2004|
|Primary Completion Date :||January 2006|
|Study Completion Date :||January 2006|
U.S. FDA Resources
- Mean diurnal intraocular pressure at month 3
- Individual intraocular pressures measured at 08:00, 12:00 and 16:00 at month 3.
- Reduction from baseline in mean diurnal intraocular pressure and individual timepoints.
- Visual acuity, Slit lamp biomicroscopy and adverse events during 3 months.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00372827
|Mainz, Germany, 55131|
|Study Director:||Anna Grau||Study Manager|